Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_provenance.
- NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_assertion description "[Studies presented or published during the European Society for Medical Oncology conference demonstrate that combining BRAF and MEK inhibitors improves progression-free and overall survival--and lowers the risk of resistance and toxicities--in patients with metastatic melanoma with BRAF V600E or V600K mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_provenance.
- NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_assertion evidence source_evidence_literature NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_provenance.
- NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_assertion SIO_000772 25477091 NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_provenance.
- NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_assertion wasDerivedFrom befree-2016 NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_provenance.
- NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_assertion wasGeneratedBy ECO_0000203 NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_provenance.
- befree-2016 importedOn "2016-02-19" NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_provenance.